MiNK Therapeutics Stock Jumps on Pediatric Cancer Deal and Funding

Key Points

MiNK Therapeutics shares rallied sharply after announcing a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.
The deal includes approximately $1.1 million in non-dilutive funding for MiNK and a double-digit share of downstream commercial revenues.
The therapy aims to use iNKT cells to target tumors precisely while activating immune responses in the tumor microenvironment, part of MiNK's broader platform strategy.
MiNK's iNKT platform offers potential advantages as an allogeneic, off-the-shelf therapy that doesn't require HLA matching or toxic pre-treatment chemotherapy.
The company recently published encouraging case data showing a complete and durable remission in a patient with refractory testicular cancer treated with its iNKT cell therapy.

Get MiNK Therapeutics Alerts

Weekly insights + SMS alerts

Here's a nice way to start your Tuesday: watching your stock jump nearly 50% before the market even opens. That's what happened to shareholders of MiNK Therapeutics Inc. (INKT) after the company announced a strategic collaboration to develop a cell therapy for pediatric cancers.

The biopharma firm is teaming up with C-Further to work on a PRAME-targeted TCR-engineered iNKT cell therapy for kids with cancer. If you're wondering what all those acronyms mean, don't worry—we'll get to that. The important part is that MiNK gets about $1.1 million in non-dilutive funding to support the development, plus a double-digit share of any commercial revenues down the line.

Think of it as getting paid to work on something that could help sick children, while keeping the option to work on other cancer targets independently. Not a bad deal.

Why This Approach Matters

The program aims to use the biology of iNKT cells—a type of immune cell—to target tumors precisely while activating coordinated immune responses within the tumor microenvironment. It's part of MiNK's broader strategy to apply its iNKT platform across validated tumor antigens, with a focus on safety and long-term survivorship.

Here's where it gets interesting for investors and patients alike: iNKT cells are what's called an allogeneic, off-the-shelf therapy. Translation: they come from healthy donors, can be manufactured in advance, frozen, and delivered to patients when needed. No HLA matching required, no toxic lymphodepleting chemotherapy needed beforehand. That's potentially a big advantage over some traditional cell therapies that require more customization and harsh pre-treatment.

The Backstory: Encouraging Data

This isn't MiNK's first rodeo with iNKT cells. Back in July 2025, the company announced the publication of a landmark case in Nature's Oncogene. The data described something pretty remarkable: a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer after treatment with agenT-797, MiNK's allogeneic iNKT cell therapy.

The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and the treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease. That's the kind of data that makes biotech investors sit up and take notice.

So when MiNK announces a new collaboration in pediatric cancers—backed by funding and revenue sharing—it's not coming out of nowhere. There's some promising science behind it.

As for the stock reaction: MiNK Therapeutics shares were up 48.33% at $15.50 on Tuesday, according to market data. When you're developing therapies that could help children with cancer and showing promising early results, people tend to pay attention.